A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease is a research paper published in Nature Medicine (2021). On theSindex it has a DataRank of 0.885. It has been cited 365 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.885
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →U.S. Department of Health & Human Services | NIH | National Institute on Aging
Grant: U01AG042791
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Grant: U01AG042791-S1
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Grant: R01AG046179, R01AG053267-S1
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Grant: U19AG032438
NIA NIH HHS
Grant: P01 AG003991
NIA NIH HHS
Grant: P01 AG026276
NIA NIH HHS
Grant: R01 AG053267
NIA NIH HHS
Grant: P30 AG066508
NIA NIH HHS
Grant: U19 AG024904
NIA NIH HHS
Grant: P30 AG066444
NIA NIH HHS
Grant: UF1 AG032438
NIH HHS
Grant: S10 OD025214
NIA NIH HHS
Grant: R01 AG046179
U.S. Department of Health & Human Services | NIH | National Institute on Aging
Alzheimer’s Association
FWCI
31.16
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles
Additional file 1 of Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles
Additional file 1 of Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
Additional file 1 of Fully automated and highly specific plasma β-amyloid immunoassays predict β-amyloid status defined by amyloid positron emission tomography with high accuracy
Additional file 1 of Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis
Additional file 1 of Brain pharmacokinetics of mono- and bispecific amyloid-β antibodies in wild-type and Alzheimer’s disease mice measured by high cut-off microdialysis
Additional file 1 of Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases
Additional file 1 of Histone deacetylase inhibitors VPA and WT161 ameliorate the pathological features and cognitive impairments of the APP/PS1 Alzheimer’s disease mouse model by regulating the expression of APP secretases